Tag Archives: Pain

Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.”, says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).







United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com


Dallas, Texas (PRWEB) December 02, 2014

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.

Complete report available at http://www.marketreportsonline.com/376611.html.

Segment Coverage

    Oxycodone
    Hydrocodone
    Morphine
    Hydromorphone
    Fentanyl
    Dihydrocodeine
    Methadone

Company Coverage

    Zogenix Inc.
    Egalet Corporation
    NektarTheropeutics

Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating.

The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.

Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=376611.

Major points from Table of Contents (http://www.marketreportsonline.com/376611-toc.html) are listed below:

List of Tables and Figures

Table 1: Types of Acute and Chronic pain

Table 2: WHO Guidelines for Pain Therapy

Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions)

Figure 2: US Opioid Sales in Chronic Pain Therapy Market – Forecast: 2014F-2019F (US$ B)

Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion)

Figure 4: Oxycodone Market: Share of Leading Players (2027)

Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion)

Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million)

Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 8: US Morphine Market: by value- 2009-13 (in US$ million)

Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 10: US Long- Acting Morphine Market: 2014

Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million)

Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion)

Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion)

Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion)

Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion)

Explore more reports on Pharmaceuticals Market at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:

MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the medical devices market, MarketReportsOnline.com offers research studies on pharmaceuticals, chemicals, agriculture, environment, biotechnology, public sector, retail, food and beverages, energy and power, semiconductor and electronics, advanced materials, banking and financial services, mining & utilities, consumer goods, agriculture, travel & hospitality, healthcare and much more.







United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com


Dallas, Texas (PRWEB) December 02, 2014

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.

Complete report available at http://www.marketreportsonline.com/376611.html.

Segment Coverage

    Oxycodone
    Hydrocodone
    Morphine
    Hydromorphone
    Fentanyl
    Dihydrocodeine
    Methadone

Company Coverage

    Zogenix Inc.
    Egalet Corporation
    NektarTheropeutics

Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating.

The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.

Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=376611.

Major points from Table of Contents (http://www.marketreportsonline.com/376611-toc.html) are listed below:

List of Tables and Figures

Table 1: Types of Acute and Chronic pain

Table 2: WHO Guidelines for Pain Therapy

Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions)

Figure 2: US Opioid Sales in Chronic Pain Therapy Market – Forecast: 2014F-2019F (US$ B)

Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion)

Figure 4: Oxycodone Market: Share of Leading Players (2027)

Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion)

Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million)

Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 8: US Morphine Market: by value- 2009-13 (in US$ million)

Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 10: US Long- Acting Morphine Market: 2014

Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million)

Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion)

Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion)

Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion)

Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion)

Explore more reports on Pharmaceuticals Market at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:

MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the medical devices market, MarketReportsOnline.com offers research studies on pharmaceuticals, chemicals, agriculture, environment, biotechnology, public sector, retail, food and beverages, energy and power, semiconductor and electronics, advanced materials, banking and financial services, mining & utilities, consumer goods, agriculture, travel & hospitality, healthcare and much more.







Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.”, says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).







United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com


Dallas, Texas (PRWEB) December 02, 2014

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.

Complete report available at http://www.marketreportsonline.com/376611.html.

Segment Coverage

    Oxycodone
    Hydrocodone
    Morphine
    Hydromorphone
    Fentanyl
    Dihydrocodeine
    Methadone

Company Coverage

    Zogenix Inc.
    Egalet Corporation
    NektarTheropeutics

Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating.

The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.

Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=376611.

Major points from Table of Contents (http://www.marketreportsonline.com/376611-toc.html) are listed below:

List of Tables and Figures

Table 1: Types of Acute and Chronic pain

Table 2: WHO Guidelines for Pain Therapy

Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions)

Figure 2: US Opioid Sales in Chronic Pain Therapy Market – Forecast: 2014F-2019F (US$ B)

Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion)

Figure 4: Oxycodone Market: Share of Leading Players (2027)

Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion)

Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million)

Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 8: US Morphine Market: by value- 2009-13 (in US$ million)

Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 10: US Long- Acting Morphine Market: 2014

Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million)

Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion)

Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion)

Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion)

Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion)

Explore more reports on Pharmaceuticals Market at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:

MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the medical devices market, MarketReportsOnline.com offers research studies on pharmaceuticals, chemicals, agriculture, environment, biotechnology, public sector, retail, food and beverages, energy and power, semiconductor and electronics, advanced materials, banking and financial services, mining & utilities, consumer goods, agriculture, travel & hospitality, healthcare and much more.







United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com


Dallas, Texas (PRWEB) December 02, 2014

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.

Complete report available at http://www.marketreportsonline.com/376611.html.

Segment Coverage

    Oxycodone
    Hydrocodone
    Morphine
    Hydromorphone
    Fentanyl
    Dihydrocodeine
    Methadone

Company Coverage

    Zogenix Inc.
    Egalet Corporation
    NektarTheropeutics

Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating.

The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.

Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=376611.

Major points from Table of Contents (http://www.marketreportsonline.com/376611-toc.html) are listed below:

List of Tables and Figures

Table 1: Types of Acute and Chronic pain

Table 2: WHO Guidelines for Pain Therapy

Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions)

Figure 2: US Opioid Sales in Chronic Pain Therapy Market – Forecast: 2014F-2019F (US$ B)

Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion)

Figure 4: Oxycodone Market: Share of Leading Players (2027)

Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion)

Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million)

Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 8: US Morphine Market: by value- 2009-13 (in US$ million)

Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 10: US Long- Acting Morphine Market: 2014

Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million)

Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million)

Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion)

Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion)

Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion)

Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion)

Explore more reports on Pharmaceuticals Market at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:

MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the medical devices market, MarketReportsOnline.com offers research studies on pharmaceuticals, chemicals, agriculture, environment, biotechnology, public sector, retail, food and beverages, energy and power, semiconductor and electronics, advanced materials, banking and financial services, mining & utilities, consumer goods, agriculture, travel & hospitality, healthcare and much more.







Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.”, says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).







Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.”, says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).







Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.”, says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).







Proove Biosciences has presented at the Pain Society of the Carolinas Annual Meeting

IRVINE, CA (PRWEB) December 10, 2014

Proove Biosciences, a commercial and research leader in Personalized Medicine, presented research conducted through their genetic testing for drug responses.

The Pain Society of the Carolinas Annual Meeting focuses on the rapidly expanding field of pain management.

Genetic factors are believed to account for 20-95% of observed variation in a patient’s response to prescription drugs. However, this is not typically explored before the commencement of a prescription regime, as the role of unique genes is poorly understood. Overdoses of opioids such as Oxycodone and Hydrocodone are the second leading cause of accidental death in the United States. The misuse and abuse of opioid medication is seen as a major part of the Public Health Crisis of Prescription Drug Abuse.

In this study, conducted with data from a population of 1580 pain patients using oxycodone only, it is suggested that ANKK1 and DBH may play an active role in the observed differences in the therapeutic response to the use of Oxycodone. Also suggested is that response to opioid medications may be more influenced by the genes of the mesolimbic neural circuitry than previously thought.

“This new information could help guide future prescription decisions to avoid misuse and abuse.”, says Bilikis.

About Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We envision a future where physicians will know how patients are likely to respond to medications before writing a prescription. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).